TIMING OF EU5 & US ORPHAN DRUG APPROVALS AND PRMA BETWEEN 2009 AND 2013

被引：0
|
作者：
Mycka, J. [1 ]
Dellamano, R. [2 ]
Lobb, W. [1 ]
Dalal, N. [1 ]
Pereira, E. [1 ]
Dellamano, L. [2 ]
Sagaydachnaya, O. [1 ]
Lue, J. [1 ]
机构：
[1] Med Mkt Econ LLC MME, Montclair, NJ USA
[2] ValueVector, Milan, Italy
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 03期
关键词：
D O I：
10.1016/j.jval.2015.03.1775
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSY77
引用
收藏
页码：A305 / A305
页数：1
相关论文
共 50 条
  • [1] THE CHANGING LANDSCAPE OF ORPHAN DRUG PROVISION IN THE EU5 AND THE UNITED STATES
    McConkey, D.
    VALUE IN HEALTH, 2011, 14 (03) : A18 - A19
  • [2] TIME FOR REIMBURSEMENT FOR ORPHAN DRUGS IN EU5
    Prada, M.
    Berard, I
    Walzer, S.
    Darba, J.
    Greenwood, B.
    VALUE IN HEALTH, 2018, 21 : S264 - S264
  • [3] ORPHAN DRUG ACCESS AND REIMBURSEMENT IN THE EU5: CYSTIC FIBROSIS AND DUCHENNE MUSCULAR DYSTROPHY
    Privolnev, Y.
    Cox, J.
    Breen, M.
    Reyes, A.
    VALUE IN HEALTH, 2018, 21 : S459 - S459
  • [4] REGULATORY APPROVAL TO PATIENT ACCESS: AN EVALUATION OF EU5 AND US NATIONAL TIMING DIFFERENCES - AN UPDATE (2009-2015)
    Mycka, J.
    Dellamano, R.
    Lobb, W.
    Dalal, N.
    Dellamano, L.
    Sagaydachnaya, O.
    Mora, M.
    Sudol, M.
    Lue, J.
    VALUE IN HEALTH, 2016, 19 (03) : A281 - A281
  • [5] ASSESSING THE ACCEPTANCE OF POPULATION ADJUSTMENT METHODS IN ORPHAN DRUG HTA SUBMISSIONS IN THE EU5 AND THE NORDICS
    Kopsida, E.
    Tadic, I
    Lindblom, J.
    Medin, E.
    VALUE IN HEALTH, 2020, 23 : S706 - S706
  • [6] IMPLICATIONS OF TOTAL BUDGET IMPACT ON ONCOLOGY DRUG PRICING IN THE US AND EU5
    Xue, Y.
    Degun, R.
    Montilva, J.
    VALUE IN HEALTH, 2016, 19 (07) : A752 - A752
  • [7] REGULATORY APPROVAL TO PATIENT ACCESS, AN EVALUATION OF EU5 AND US NATIONAL TIMING DIFFERENCES
    Mycka, J.
    Dellamano, R.
    Lobb, W.
    Dalal, N.
    Pereira, E.
    Dellamano, L.
    Sagaydachnaya, O.
    VALUE IN HEALTH, 2014, 17 (07) : A794 - A4795
  • [8] MARKET ACCESS TRENDS OF PHARMACEUTICAL PRODUCTS IN THE EU5 AND US (2009-2019)
    Mycka, J. M.
    Dellamano, R.
    Lobb, W.
    Dalal, N.
    Dellamano, L.
    Pereira, E.
    VALUE IN HEALTH, 2021, 24 : S151 - S151
  • [9] MARKET ACCESS TRENDS ACROSS THE EU5 AND US: 2009 TO 2018-AN UPDATE
    Mycka, J.
    Lobb, W.
    Dellamano, R.
    Dalal, N.
    Dellamano, L.
    Pereira, E.
    Mora, M.
    Pollere, D.
    Papa, R.
    VALUE IN HEALTH, 2019, 22 : S300 - S300
  • [10] TIME TO REIMBURSEMENT FOR ORPHAN DRUGS IN EU5 IN THE LAST FIVE YEARS
    Molchanova, E.
    Benazet, F.
    Vollmer, L.
    Pomares, E.
    Danev, V
    Prada, M.
    VALUE IN HEALTH, 2020, 23 : S701 - S701
12345